H.C. Wainwright reiterates Achieve Life Sciences stock rating on trial data
H.C. Wainwright reiterated a Buy rating and $12.00 price target for Achieve Life Sciences (ACHV) after 52-week ORCA-OL study data showed 31% of patients achieved smoking abstinence. The stock is up 57% in six months, trading at $6.50. Analysts expect a 2026 NDA resubmission and 2027 approval. ACHV appointed Benjamin Halladay as CFO, with Stifel and Morgan Stanley also initiating coverage with Buy ratings and targets of $18.00 and $13.00, respectively.
How this was made
The 30-second read
Why it matters
The trial data provide the first substantive efficacy signal, prompting analyst upgrades and a renewed focus on the upcoming NDA filing.
Market read
The new efficacy data could catalyze a price rally for ACHV and influence sentiment in the biotech sector.
What to watch
Potential competition from other nicotine‑cessation therapies and the need for a successful NDA resubmission.
Background
Achieve Life Sciences (NASDAQ:ACHV) is developing cytisinicline for smoking cessation; the ORCA‑OL study is a follow‑up to earlier trials.
Ticker impact
H.C. Wainwright reiterated a Buy rating and $12 price target after Achieve Life Sciences released 52‑week efficacy data from the ORCA‑OL trial showing 31% abstinence, a new primary disclosure.
upward pressure as investors price in improved efficacy and upcoming NDA resubmission.
First report of pivotal trial data for a biotech with a pending NDA; analysts upgraded and raised targets, indicating material upside.
Market effects
Positive data may lift the broader smoking‑cessation biotech sector.
Limited to U.S. biotech investors; no broader regional effect.
Modest global relevance as the drug targets a worldwide market.
Counterpoint
If the data does not translate into regulatory approval, the upside may be overstated.
Key entities
- companyAchieve Life Sciences
Biotech developing cytisinicline for nicotine addiction.
- analystH.C. Wainwright
Equity research firm that reiterated a Buy rating on ACHV.
